Company intelligence / Profile preview

GPN Vaccines

Adelaide / Yarralumla, South Australia / Australian Capital Territory, Australiagpnvaccines.com ↗

Ownership: Private
Employees: ~24
Development stage: Phase 1

Overview

GPN Vaccines has completed a first-in-human study with its universal pneumococcal vaccine candidate Gamma-PN and has begun or will soon begin a study on the durability of immune response up to one year after dosing. The company aims to provide broad protection against all known serotypes of S. pneumoniae, addressing limitations of current vaccines that cover only a subset of strains. Early clinical results have enabled progression toward Phase 2 trials and attracted significant grant funding for further development.

No published efficacy data yet; focus remains on safety and immunogenicity.

Therapeutic areas: Infectious Diseases
Modalities: Prophylactic vaccines (inactivated bacterial vaccines)
Industry: Biotech

Drug pipeline

3 assets

gamma-pn3

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed publicly as of May 2025; received CUREator Program funding from Brandon BioCatalyst supported by CSIRO and Medical Research Future Fund.

Beyond the preview

Go deeper on GPN Vaccines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPN Vaccines.

Explore the full profile